Skip to main content
European Commission logo print header

Personalized Neurostimulation Approach for the Treatment of Depression

Project description

Portable device opens new doors for the treatment of depression

Depression affects hundreds of millions of people worldwide, but customised treatment options do not exist, and up to 50 % of major depression cases remain untreated in Europe alone. Denmark-based company PlatoScience has developed a plug and play device based on transcranial direct current neurostimulation for a personalised treatment of depression. A portable neurostimulation headset with programmable electrodes allows tracking by health professionals as well as cloud-based data collection and analysis. The device includes online neuroimaging by electroencephalogram, measuring the electrophysiological data during stimulation. The EU-funded PLATOSCIENCE project is providing support for phase 1, which involves establishing partnerships with relevant stakeholders, setting up a regulatory strategy and developing a commercialisation plan.


Depression currently affects more than 300 million people worldwide, that is an increase of over 18% between 2005 and 2015. Moreover, 50% of major depressions are untreated in Europe, costing about €170Bn per year. Despite subject´s relevance, there are not any efficient nor customized treatment options, these falling often within conventional solutions (e.g. cognitive techniques), medication or neurostimulation techniques that do not acknowledge an individual rehabilitation for the patient.

Platoscience has developed the world’s first plug n’ play device based on trans-cranial direct current neurostimulation (tDCS) for a personalised at-home treatment of depression. The patent-protected device, PlatoCure, consists of a portable neurostimulation headset with two programmable electrodes, easy to use and control, connected to an app to be tracked by health professionals and for cloud data collection and predictive analytics to improve individual treatment. PlatoCure also includes online neuroimaging by electroencephalogram (EEG) that enables measuring of electrophysiological data during stimulation. This yields a significant advantage of PlatoCure against competition, strengthening market introduction to become the standard treatment device for moderate to severe depression, yielding benefits for a large group of stakeholders, including patients, medical professionals, hospitals and clinics.

The SME Ph1 will be crucial for: i) establishing partnerships with relevant stakeholders on an international level in the medical segment, ii) setting up a regulatory strategy and iii) developing a clear commercialisation strategy. Hereafter, PlatoScience will be able to start SME Ph 2 focusing on the clinical validation of the device with hospitals and clinics.
Until the end of 2026, we expect a cumulative revenue of €10,1 million, gross profit of €8,25 million and to create 15 qualified new jobs, within 5 years of commercialization.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Danmark Hovedstaden Byen København
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 71 429,00